Your browser doesn't support javascript.
Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study.
Scarduelli, Cleante; Inglese, Francesco; Beccaria, Massimiliano; Spreafico, Fabio; Garuti, Martina; Pecoriello, Antonietta; Cervi, Giulia; Greco, Graziana; Scarduelli, Sara; Lucchini, Giuseppe; De Donno, Giuseppe; Borghi, Claudio.
  • Scarduelli C; ASST Mantova. cleante@libero.it.
  • Inglese F; ASST Mantova Italy. francesco.inglese@asst-mantova.it.
  • Beccaria M; Pulmonology and Respiratory Intensive Care Unit ASST Mantova . massimiliano.beccaria@asst-mantova.it.
  • Spreafico F; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. fabio.spreafico@asst-mantova.it.
  • Garuti M; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. martina.garuti@asst-mantova.it.
  • Pecoriello A; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. antonietta.pecoriello@asst-mantova.it.
  • Cervi G; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. giulia.cervi@asst-mantova.it.
  • Greco G; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. graziana.greco@asst-mantova.it.
  • Scarduelli S; Internal Medicine Department of Medical and Surgical Sciences Bologna University . saran.y@hotmail.it.
  • Lucchini G; Bio-statistical Service, ASST, Mantova. giuseppe.lucchini@asst-mantova.it.
  • De Donno G; Pulmonology and Respiratory Intensive Care Unit ASST Mantova. giuseppe.dedonno@asst-mantova.it.
  • Borghi C; Internal Medicine Department of Medical and Surgical Sciences Bologna University. claudio.borghi@unibo.it.
Monaldi Arch Chest Dis ; 91(3)2021 Mar 16.
Article in English | MEDLINE | ID: covidwho-1138812
ABSTRACT
Coronavirus disease (COVID-19) may predispose patients to pulmonary embolism (PE), despite standard thromboprophylaxis. Our retrospective study aimed to report the prevalence of PE in patients with COVID-19 and severe respiratory failure (SRF) treated with intermediate- to full-dose enoxaparin. We analyzed data from patients with COVID-19 pneumonia and SRF admitted to our Respiratory Intensive Care Unit (RICU) from February 27 to April 20, 2020. All patients received at least intermediate-dose enoxaparin (40 mg twice daily). Computed tomography pulmonary angiography (CTPA) was used to detect PE. Ninety-two patients with COVID-19 pneumonia and SRF were admitted to our RICU. Twenty-two patients underwent CTPA (24 %), 11 of whom had PEs (12%). We hypothesize that the enoxaparin treatment may be responsible for the lower prevalence of PE as compared to previous reports of similar patients, even if our report had several limitations, mainly the small sample size.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Embolism / Venous Thromboembolism / COVID-19 Type of study: Observational study Limits: Humans Language: English Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Embolism / Venous Thromboembolism / COVID-19 Type of study: Observational study Limits: Humans Language: English Year: 2021 Document Type: Article